Koji Sasaki (佐々木　宏治)

Koji Sasaki (佐々木　宏治)

M D Anderson Cancer Center University of Texas - Houston / United States
Others
AD Scientific Index ID: 1406890
MD Anderson Cancer Center
person_outline Koji Sasaki (佐々木　宏治)'s MOST POPULAR ARTICLES
1-) Ibrutinib and venetoclax for first-line treatment of CLLN Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ...New England Journal of Medicine 380 (22), 2095-2103, 20193802019
2-) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsK Sasaki, SS Strom, S O\\\\\\\\\\\\\\\'Brien, E Jabbour, F Ravandi, M Konopleva, ...The Lancet Haematology 2 (5), e186-e193, 20153082015
3-) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyE Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ...The Lancet Oncology 16 (15), 1547-1555, 20153022015
4-) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ...The Lancet Haematology 7 (10), e724-e736, 20202852020
5-) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsD Rea, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, ...Blood, The Journal of the American Society of Hematology 138 (21), 2031-2041, 20212692021